Nortadalafil

Nortadalafil (also known as demethyltadalafil or n-desmethyl tadalafil) is a synthetic analog of tadalafil, a long-acting phosphodiesterase type 5 (PDE5) inhibitor used clinically for erectile dysfunction and pulmonary arterial hypertension. Structurally it is the des-methyl (nor) variant of tadalafil, lacking the N-methyl group on the tadalafil scaffold; it belongs to a broader family of tadalafil analogs that share the core PDE5-inhibiting pharmacophore ^[1][2].

Much of the peer-reviewed literature on nortadalafil comes from analytical and forensic chemistry, because it and related analogs are recurrent undeclared adulterants in dietary and herbal supplements marketed for sexual enhancement. Investigators have isolated and structurally characterized several such analogs, including N-cyclohexyl nortadalafil ^[1], N-cyclopentyl nortadalafil ^[2], and bisprenortadalafil found alongside nortadalafil ^[3], using high-resolution mass spectrometry and nuclear magnetic resonance. Configuration studies have confirmed that nortadalafil found in products typically carries the 6R,12aR stereochemistry, the same configuration associated with the most potent PDE5 inhibition among tadalafil stereoisomers ^[4].

Pharmacologically, nortadalafil is expected to act like tadalafil as a PDE5 inhibitor. Tadalafil is a long-acting agent that raises cyclic GMP and protein kinase G activity ^[5], and mechanistic studies of PDE5 inhibitors, including tadalafil, show that they induce a conformational change and feedback phosphorylation of the enzyme that shapes cyclic GMP signaling ^[6]. The nor variant is reported to retain the prolonged duration characteristic of tadalafil.

Nortadalafil is sold as a research chemical and is not an approved medicine; its appearance in commerce is largely as an unapproved analog or supplement adulterant. Because it shares tadalafil's mechanism, it carries the same central safety consideration; PDE5 inhibitors are hazardous when combined with nitrate medications due to the risk of profound blood pressure lowering.

Nortadalafil is an unapproved research analogue of tadalafil and shares PDE5-inhibitor risks: it must not be combined with nitrates or guanylate-cyclase stimulators because of the danger of severe hypotension, and it can cause headache, flushing, priapism, and rare sudden vision or hearing loss. As an untested analogue often found as an adulterant in unregulated products, its true potency, purity, and pharmacology are not characterized, making unintended overdose and interaction risks substantial. It has not undergone formal human safety evaluation.

Nortadalafil, also called n-desmethyltadalafil or demethyltadalafil, is a close structural analog and a human metabolite of tadalafil, the long-acting PDE5 inhibitor developed by ICOS and Eli Lilly and approved as Cialis in 2003. Unlike its parent, nortadalafil has never itself been developed or approved as a pharmaceutical product; its documented history lies almost entirely in analytical toxicology.

Since the mid-2000s it has repeatedly surfaced as a designer analog used to adulterate dietary supplements marketed for sexual enhancement, and regulators and forensic chemists have identified it and related tadalafil analogues in such products on numerous occasions. Its properties as an approved medicine are therefore undocumented, and what is known derives from its close resemblance to tadalafil and from studies of contaminated supplements. Analytical work has noted that the form most often detected carries the 6R,12aR configuration associated with the strongest PDE5 inhibitory activity.

Nortadalafil draws interest because it shares the pharmacology that made tadalafil famous; a long-acting PDE5 inhibitor capable of sustaining smooth-muscle relaxation and improved blood flow well beyond a single day. In principle it offers the same familiar benefits, and analytical studies suggest the form usually detected carries tadalafil's most active stereochemistry. Candor is essential here, however; nortadalafil is not an approved medicine but a grey-market analog most often encountered as a hidden adulterant in supplements, where dose and purity are unverified and quality control is absent. Like every PDE5 inhibitor it carries the serious, non-negotiable caution that it must never be taken with nitrate heart medications, a combination that can cause a dangerous fall in blood pressure. Its appeal is real, but so are the reasons for caution.